(Total Views: 1332)
Posted On: 03/21/2019 3:11:16 PM
Post# of 154806
I'm trying to figure out this "3+3" design for phase 1.
I've seen a couple graphics,
Quote:
Phase Ib is a dose escalation phase with 3 dose levels (cohorts) of leronlimab (PRO 140) administered in combination with a fixed dose of carboplatin at AUC 5. This dose finding portion of study will follow a "3+3" designed to determine the maximum tolerated dose (MTD) of leronlimab (PRO 140) administered as subcutaneous injection in subjects with histologically confirmed mTNBC that express CCR5.
I've seen a couple graphics,
(0)
(0)
